Clinical trials
Paclitaxel clinical trials
Below are recruiting paclitaxel clinical trials, each written for real people, not researchers. We’re tracking 669 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05699811RecruitingPhase 1/Phase 2
Test of special immune-support cells for solid tumors
This study tests lab-made mesenchymal stromal cells that release interferon alpha (IFNα) for people with locally advanced or metastatic solid cancers. It’s designed to see if this treatment can help when standard treatments have failed or don’t have guideline options.
BeijingAges 18–75 - NCT05687357RecruitingPhase 2
Tislelizumab plus chemoradiation before surgery for stomach cancer
This Phase 2 trial studies giving tislelizumab (an immune therapy) together with pre-surgery chemoradiation for locally advanced stomach or GEJ (esophagus-stomach junction) adenocarcinoma. It compares this approach to the standard treatment (chemoradiation plus surgery) to see if it improves outcomes.
Wuhan, HubeiAges 18–75 - NCT02429700RecruitingPhase 3
Chemo comparison for certain ovarian tumors after surgery
This Phase 3 trial tests two chemotherapy regimens (TC vs BEP) for women with malignant sex cord-stromal tumors of the ovary. It aims to see which treatment works better after you’ve had initial surgery to diagnose and/or remove tumor.
Jinan, ShandongAges 14–65 - NCT02429687RecruitingPhase 3
Testing two chemo regimens for ovarian germ cell tumors
This Phase 3 trial compares two different chemotherapy approaches for women with ovarian sex cord–stromal germ cell tumors. It aims to see which treatment works better and is safer for newly diagnosed stage IIA to IVB disease after surgery.
Jinan, ShandongAges 14–65 - NCT05447702RecruitingPhase 2
Testes pre-surgery treatment for triple-negative breast cancer
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
Chengdu, SichuanAges 18–75 - NCT05083247RecruitingPhase 2
Pre-surgery chemotherapy plus targeted radiation for borderline pancreatic cancer
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
AntwerpAges 18 years+ - NCT05862168RecruitingPhase 2
Tislelizumab with chemotherapy before surgery for oral cancer
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
HangzhouAges 18–75 - NCT05981014RecruitingPhase 1/Phase 2
Immune cells from lymph nodes for HER2-negative breast cancer
This trial tests whether taking immune cells from your lymph nodes and giving them back to you can help shrink breast cancer that has not responded fully to initial chemotherapy. It is for women with HER2-negative breast cancer who have had stable disease after two cycles of a standard chemotherapy combination.
Guangzhou, GuangdongAges 18–70 - NCT05981001RecruitingPhase 1/Phase 2
Experimental cell therapy for advanced HER2-negative breast cancer
This study tests a new treatment for advanced HER2-negative breast cancer. Doctors will take immune cells from lymph nodes near your tumor, grow them in a lab, and then give them back to you along with chemotherapy and immunotherapy. This approach aims to help your body fight the cancer more effectively.
Guangzhou, GuangdongAges 18–70 - NCT06006650RecruitingPhase 2
Neoadjuvant therapy for stage II-IVA esophageal cancer
This trial tests a treatment given before surgery for patients with a type of esophageal cancer called squamous cell carcinoma, stages II to IVA. The goal is to see if this approach can improve outcomes.
Xi'an, ShaanxiAges 18–75 - NCT03534713RecruitingPhase 3
Cervical cancer treatment plan after lymph node spread
This trial tests a specific chemotherapy start (induction) followed by standard treatment for cervical cancer that has spread to lymph nodes near the aorta. It may help improve cancer control compared with standard timing/approach.
BordeauxAges 18 years+ - NCT05832827RecruitingPhase 2
First treatment combo for thymic cancer using pembrolizumab plus drugs
This Phase 2 study tests a first (initial) treatment combination of pembrolizumab with three other drugs (carboplatin, paclitaxel, and lenvatinib) for advanced or recurrent thymic carcinoma. It aims to shrink tumors and improve control of the cancer when standard chemotherapy has not yet been tried for your situation.
Chūō, TokyoAges 18 years+ - NCT05624099RecruitingPhase 2
Camrelizumab plus chemoradiotherapy for advanced esophageal cancer
This study tests whether adding camrelizumab (an immune treatment) to standard chemoradiotherapy can control advanced esophageal squamous cell cancer. It is meant for people who have not had any prior whole-course cancer medicines for this cancer stage.
FuzhouAges 18–75 - NCT06102772Recruiting
Combination immunotherapy and targeted therapy for advanced gastric cancer
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06102759Recruiting
Study of adebrelimab and fruquintinib plus chemo for advanced stomach cancer after PD-1 failure
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06104007Recruiting
Genoss balloon for narrowed heart stents
This study follows patients who have already received a special drug-coated balloon (Genoss® DCB) to treat a re-narrowed heart stent. It aims to see how safe and effective the balloon is in the long term.
SeoulAges 19 years+ - NCT06121570RecruitingPhase 1
Study of immune cells from lymph nodes for HER2-negative breast cancer
This trial tests whether using a patient's own immune cells from lymph nodes near the tumor, given as a treatment before surgery, can help shrink HER2-negative breast cancer. It is for people whose cancer has not responded fully to two cycles of initial chemotherapy.
Guangzhou, GuangdongAges 18–70 - NCT06122493RecruitingPhase 2
Better treatment for advanced esophageal cancer
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05125055RecruitingPhase 2/Phase 3
Test new throat cancer treatment before surgery
This trial tests giving anti–PD-1 immunotherapy plus a drug called TP before surgery for oral squamous cell carcinoma (mouth/throat cancer). The goal is to see whether this pre-surgery treatment improves how much the tumor responds under the microscope.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT02988921Recruiting
MRI and CT planning for esophagus or stomach-junction cancer treatment
This study checks whether MRI and CT scans can better measure how esophageal or stomach-junction tumors respond during chemoradiotherapy and help doctors map the exact treatment area. It may help improve targeting while you receive standard treatment.
BeijingAges 18 years+ - NCT06017284RecruitingPhase 3
Thalidomide for nausea in pancreatic cancer patients
This trial tests whether adding thalidomide to standard chemotherapy can help reduce nausea and vomiting in people with advanced pancreatic cancer. It is for patients who have not yet received any cancer treatment.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05978648RecruitingPhase 2
Trilaciclib for early-stage HR-negative breast cancer after surgery
This trial tests if adding trilaciclib to standard chemotherapy after surgery can help people with hormone receptor-negative breast cancer. It aims to reduce side effects and improve treatment outcomes.
Guangzhou, GangdongAges 18 years+ - NCT05681650RecruitingPhase 1/Phase 2
HER2-targeted CAR-T for HER2-positive advanced solid tumors
This trial tests a new immune-cell therapy (CAR-T) that targets a protein called HER2 in people with advanced or metastatic solid cancers. It may help shrink tumors and control the disease after standard treatments have failed or when there is no clear standard option.
Beijing, Beijing MunicipalityAges 18–75 - NCT06173986RecruitingPhase 1/Phase 2
Immunotherapy plus chemoradiation for advanced esophageal cancer
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
ShanghaiAges 18–75
Hear when a new Paclitaxel trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for paclitaxel?
- Yes. Clin2 currently lists 669 recruiting paclitaxel studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a paclitaxel trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a paclitaxel trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.